本季度信息
根据公告，药明生物在截至2025年12月31日止年度实现营收人民币217.90亿元，同比增长16.7%。公告显示，经调整净利润（Non-GAAP）约为人民币65.86亿元，同比增长22.0%。同期毛利率达46.0%，较上年同期提升5个百分点。公告称，基于精益运营管理系统与数字化方案带来的成本节约和效率提升，也为业绩增长提供了支撑。
业务分项
公司在双特异性抗体、ADC（抗体偶联药物）等快速发展的技术平台上持续布局，提供包括研究和发现服务、IND前开发服务以及临床和商业化生产服务等多环节支持。公告指出，这些先进技术平台及欧洲生产基地产能利用率上升，带动研究及生产服务收入增长。同时，公司通过投资组合获得投资收益，进一步强化整体收入表现。
高管解读
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.